CD86 and neoplasm: Raw264.7, DC2.4, or BMDCs were used to assess uptake. BMDCs were used to assess lysosomal escape, antigen cross-presentation (measured as expression of H2-Kb-SIINFEKL complexes on BMDC surface), and DC maturation (measured as CD40, CD80, and CD86 expression, as well as TNF-α and IL-12p70 secretion).C57BL/6 mice bearing either B16-OVA or B16F10 tumours were used to assess biodistribution and anticancer effects of therapeutic intra-footpad vaccine injections given 7 and 14 days after tumour inoculation.